IBKS No2 SPAC (204840) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.088x

Based on the latest financial reports, IBKS No2 SPAC (204840) has a cash flow conversion efficiency ratio of -0.088x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.73 Billion ≈ $-1.17 Million USD) by net assets (₩19.80 Billion ≈ $13.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IBKS No2 SPAC balance sheet independence to measure how much of total assets are equity-financed.

IBKS No2 SPAC - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how IBKS No2 SPAC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IBKS No2 SPAC earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

IBKS No2 SPAC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of IBKS No2 SPAC ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Pembangunan Jaya Ancol Tbk JK:PJAA	0.107x
Senko Co. Ltd KQ:347000	-0.031x
Cyan AG XETRA:CYR	0.046x
Cryosite Ltd AU:CTE	0.361x
Wing Yip Food (China) Holdings Group Limited KQ:900340	-0.005x
Korea Computer Inc KQ:054040	0.041x
Me2on Co. Ltd KQ:201490	0.027x
Heritage Global Inc NASDAQ:HGBL	-0.032x

Annual Cash Flow Conversion Efficiency for IBKS No2 SPAC (2015–2025)

The table below shows the annual cash flow conversion efficiency of IBKS No2 SPAC from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see IBKS No2 SPAC (204840) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩19.92 Billion ≈ $13.50 Million	₩-1.12 Billion ≈ $-761.78K	-0.056x	+76.12%
2024-12-31	₩19.67 Billion ≈ $13.33 Million	₩-4.65 Billion ≈ $-3.15 Million	-0.236x	+22.80%
2023-12-31	₩12.28 Billion ≈ $8.32 Million	₩-3.76 Billion ≈ $-2.55 Million	-0.306x	-288.18%
2022-12-31	₩16.09 Billion ≈ $10.90 Million	₩-1.27 Billion ≈ $-859.85K	-0.079x	+41.51%
2021-12-31	₩16.85 Billion ≈ $11.42 Million	₩-2.27 Billion ≈ $-1.54 Million	-0.135x	+27.62%
2020-12-31	₩14.31 Billion ≈ $9.70 Million	₩-2.67 Billion ≈ $-1.81 Million	-0.186x	+58.96%
2019-12-31	₩2.36 Billion ≈ $1.60 Million	₩-1.07 Billion ≈ $-726.36K	-0.454x	+6.69%
2018-12-31	₩7.82 Billion ≈ $5.30 Million	₩-3.80 Billion ≈ $-2.58 Million	-0.486x	+24.43%
2017-12-31	₩5.94 Billion ≈ $4.02 Million	₩-3.82 Billion ≈ $-2.59 Million	-0.644x	-38.10%
2016-12-31	₩8.57 Billion ≈ $5.81 Million	₩-3.99 Billion ≈ $-2.71 Million	-0.466x	-161.72%
2015-12-31	₩3.18 Billion ≈ $2.16 Million	₩2.40 Billion ≈ $1.63 Million	0.755x	--

About IBKS No2 SPAC

KQ:204840 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$43.12 Million

₩63.63 Billion KRW

Market Cap Rank

#22436 Global

#1404 in Korea

Share Price

₩824.00

Change (1 day)

-2.14%

52-Week Range

₩780.00 - ₩1274.00

All Time High

₩8655.23